Efficacy and Safety of a Low-FODMAP Diet in Combination with a Gluten-Free Diet for Adult Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.

Autor: Zhang J; School of Nursing, Yangzhou University, 136 Jiangyang Road, Yangzhou, Jiangsu, China.; Affiliated Hospital of Yangzhou University, No. 45, Taizhou Road, Yangzhou, Jiangsu, China., Yu P; School of Nursing, Yangzhou University, 136 Jiangyang Road, Yangzhou, Jiangsu, China.; Affiliated Hospital of Yangzhou University, No. 45, Taizhou Road, Yangzhou, Jiangsu, China., Xu Y; School of Nursing, Yangzhou University, 136 Jiangyang Road, Yangzhou, Jiangsu, China., Lu XY; Affiliated Hospital of Yangzhou University, No. 45, Taizhou Road, Yangzhou, Jiangsu, China., Xu Y; Affiliated Hospital of Yangzhou University, No. 45, Taizhou Road, Yangzhou, Jiangsu, China., Hang J; Affiliated Hospital of Yangzhou University, No. 45, Taizhou Road, Yangzhou, Jiangsu, China., Zhang Y; School of Nursing, Yangzhou University, 136 Jiangyang Road, Yangzhou, Jiangsu, China. yizhangyu@yzu.edu.cn.; Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou, China. yizhangyu@yzu.edu.cn.
Jazyk: angličtina
Zdroj: Digestive diseases and sciences [Dig Dis Sci] 2024 Nov; Vol. 69 (11), pp. 4124-4132. Date of Electronic Publication: 2024 Oct 15.
DOI: 10.1007/s10620-024-08671-8
Abstrakt: Background: Common gastrointestinal disease irritable bowel syndrome (IBS) is marked by symptoms like changed bowel habits, bloating, and stomach ache. A low-FODMAP combined gluten-free diet (LF-GFD) has been suggested as a possible therapy for IBS symptoms management.
Objective: This study sought to investigate whether a LF-GFD would help patients with IBS.
Methods: Strict inclusion and exclusion criteria from internet databases helped to identify clinical studies evaluating the intervention of LF-GFD in the treatment of IBS patients. Using measurements including the visual analog scale (VAS) for bloating and pain, the IBS symptom severity scale (IBS-SSS), and IBS quality of life (IBS-QoL), the main results evaluated were the efficacy of LF-GFD in reducing IBS symptoms. Furthermore assessed were the psychological impacts of LF-GFD utilizing the self- rating depression scale (SDS) and self- rating anxiety scale (SAS).
Results: A total of 437 patients (221 on LF-GFD diet and 216 on GFD) were involved in 4 randomized controlled trials and 4 cohort studies. The combined results indicated that LF-GFD reduced the VAS bloating ratings (RR = - 0.58, 95%CI - 0.92-0.23, P = 0.0010, I2 = 83%) and the VAS pain scores (RR = - 0.42, 95%CI - 0.66-0.19, P = 0.005, I2 = 58%). In addition, LF-GFD indicated a substantial enhancement in IBS-SSS scores (MD = - 1.42, 95%CI - 2.74-0.10, P = 0.03, I2 = 24%) and IBS-QoL ratings (MD = 3.75, 95%CI 0.98-6.53, P = 0.008, I2 = 33%). Moreover, the LF-GFD group showed a substantial drop in SDS (MD = - 2.56, 95%CI - 3.38-1.74, P < 0.00001, I2 = 65%) and SAS (MD = - 4.30, 95%CI - 6.53-2.24, P < 0.0001, I2 = 0%) scores compared to the GFD group.
Conclusion: LF-GFD therapy significantly enhances clinical symptoms and reduces anxiety and depression in individuals diagnosed with irritable bowel syndrome.
Competing Interests: Declarations Conflict of interest The authors declare no competing interests. Ethical approval Ethics approval number for the project: YZUHL20210116, Yangzhou University Medical Ethics Review Report.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: